Market Segmentation:
- By Source
- Embryonic Stem Cells
- Adult Stem Cells
- Induced Pluripotent Stem Cells
- Umbilical Cord Stem Cells
- Others (Amniotic Fluid Stem Cells, Placental Stem Cells)
- By Type
- Allogeneic Stem Cell Therapy
- Autologous Stem Cell Therapy
- Syngeneic Stem Cell Therapy
- By Application
- Musculoskeletal Disorders
- Cardiovascular Diseases
- Neurological Disorders
- Autoimmune Diseases
- Oncology
- Wounds and Injuries
- Others (Diabetes, Liver Diseases, Ophthalmic Disorders)
- By Technology
- Cell Acquisition
- Cell Production
- Cryopreservation
- Expansion and Sub-Culture
- Others (Cell Sorting, Quality Testing)
- By End User
- Hospitals and Clinics
- Academic and Research Institutes
- Biotechnology and Pharmaceutical Companies
- Others (Stem Cell Banks, Contract Research Organizations
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East, and Africa
Frequently Asked Questions
The current market size of the Stem Cell Therapy industry is USD 9.2 billion.
Increasing prevalence of chronic diseases, rising demand for personalized medicine, advancements in stem cell research, and growing investments in regenerative medicine.
Ethical concerns and regulatory hurdles, high cost of stem cell therapies, lack of standardized manufacturing processes, and limited reimbursement and insurance coverage.
The adult stem cell segment is the leading component segment in the Stem Cell Therapy Market due to its wide applications and reduced ethical concerns.
Mesoblast Limited, Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Holostem Terapie Avanzate S.r.l., Pluristem Therapeutics Inc., Cytori Therapeutics, Inc., Celgene Corporation, Vericel Corporation, Gamida Cell Ltd., and Athersys, Inc.
The North America region is expected to lead the Stem Cell Therapy Market, with a market size of USD 8.3 billion in 2024 and a CAGR of 12.5% during the forecast period.
Increasing prevalence of chronic diseases, rising demand for personalized medicine, advancements in stem cell research, growing investments in regenerative medicine, aging population, and technological advancements in cell culture and manufacturing processes.